摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8R,9S,10R,14S)-17-乙炔基-17-羟基-13-丙基-1,2,6,7,8,9,10,11,12,14,15,16-十二氢环戊烯并[a]菲-3-酮 | 1044-96-8

中文名称
(8R,9S,10R,14S)-17-乙炔基-17-羟基-13-丙基-1,2,6,7,8,9,10,11,12,14,15,16-十二氢环戊烯并[a]菲-3-酮
中文别名
——
英文名称
ethyl-18 hydroxy-17β nor-19 pregnene-4 yne-20 one-3
英文别名
RU 1364;13β-n-Propyl-17α-ethynyl-17β-hydroxy-gon-4en-3-one;R 1364 (Steroid);(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-propyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
(8R,9S,10R,14S)-17-乙炔基-17-羟基-13-丙基-1,2,6,7,8,9,10,11,12,14,15,16-十二氢环戊烯并[a]菲-3-酮化学式
CAS
1044-96-8
化学式
C22H30O2
mdl
——
分子量
326.479
InChiKey
NUCQOTUSUGFIDQ-ZCPXKWAGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of 13-alkyl-gon-4-ones
    申请人:Smith; Herchel
    公开号:US03959322A1
    公开(公告)日:1976-05-25
    The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
    描述了通过新的全合成方法制备13-甲基孕-4-烯和新型13-聚碳烷基孕-4-烯。通过形成在1,3,5(10),9(11)和14-位置不饱和的四环孕烷结构,选择性地在B和C环中还原,并将所产生的芳香A环化合物转化为孕-4-烯,制备具有孕激素、合成激素和雄激素活性的13-烷基孕-4-烯。
  • Applications for levonorgestrel in preparing anti-ovarian cancer products
    申请人:SHANGHAI JIAO TONG UNIVERSITY
    公开号:US10792291B2
    公开(公告)日:2020-10-06
    This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug levonorgestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that levonorgestrel has a new use as an anti-ovarian cancer medication, thus achieving a new purpose for an old drug.
    本发明公开了左炔诺孕酮在制备抗卵巢癌产品中的用途。本发明提供了左炔诺孕酮在制备治疗卵巢癌产品中的用途。通过对美国 FDA 和 CFDA 批准的药物左炔诺孕酮进行抗癌药物重新定位,本发明的实验表明,根据对各种癌细胞系(组织类型)和突变位点的非抗癌药物筛选,左炔诺孕酮具有抗卵巢癌药物的新用途,从而实现了老药新用。
  • APPLICATIONS FOR LEVONORGESTREL IN PREPARING ANTI-OVARIAN CANCER PRODUCTS
    申请人:SHANGHAI JIAO TONG UNIVERSITY
    公开号:US20180185389A1
    公开(公告)日:2018-07-05
    This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug levonorgestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that levonorgestrel has a new use as an anti-ovarian cancer medication, thus achieving a new purpose for an old drug.
  • US3959322A
    申请人:——
    公开号:US3959322A
    公开(公告)日:1976-05-25
  • Synthesis of gon-4-enes
    申请人:Smith; Herchel
    公开号:US04002746A1
    公开(公告)日:1977-01-11
    1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17.alpha.-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.
    一种具有孕激素活性的治疗组合物,其活性成分为17-脂肪族羧酸酯的17α-乙炔基-18-甲基-19-去甲睾酮,以及用于该化合物的药用载体。
查看更多